1. In Vivo
  2. >>Market Access

EU Medtech Heading For Turmoil? Navigating The Impact Of US President Trump’s Orders

 
• By Amanda Maxwell

In the wake of a series of unprecedented executive orders from US President Trump, the EU medtech industry faces significant political, regulatory and business challenges. Swift and strategic action is essential to ensure stability and safeguard patient safety.

President-elect Donald Trump speaks from his Mar-a-Lago club. (Shutterstock)
Key Takeaways
  • Trump's deregulation may outpace the EU, causing business apprehension and international friction.
  • US-based companies, especially in emerging fields, might gain an edge over EU counterparts due to lighter regulation.
  •  International regulatory initiatives and bilateral dialogues with the US could be affected by these shifts.

US President Trump’s rapid-fire executive orders, many of which impact the medtech sector, have sparked a range of reactions and concerns among European device and diagnostic stakeholders. This has highlighted...

Trump’s overriding goal is deregulation. He believes the EU has too many rules and the US government needs to rethink its own regulations too – and indeed number of regulators...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By Ashley Yeo

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Future Of 340B Rebate Models Hinges On Regulatory Decision Point

 
• By Ed Silverman

As pharmaceutical companies seek to transform how drug discounts are delivered under the 340B program, a federal ruling reinforces HRSA's authority. The industry must now wait for critical guidance from the Trump administration that could reshape compliance strategies and financial outcomes.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

More from In Vivo

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

Execs On The Move: April 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.